Group One Trading
CCCC icon

Group One Trading’s C4 Therapeutics CCCC Stock Holding History

Group One Trading’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-38,994
Closed -$91.8K – 7720
2025
Q4 		$74.5K Buy
38,994
+26,562
+214% +$62.9K ﹤0.01% 5251
2025
Q3 		$27.6K Buy
12,432
+12,417
+82,780% +$29.8K ﹤0.01% 6437
2025
Q2 		$21 Buy
+15
New +$22 ﹤0.01% 7817
2025
Q1 		– Sell
-32,883
Closed -$98.1K – 7646
2024
Q4 		$118K Buy
+32,883
New +$164K ﹤0.01% 4374
2024
Q3 		– Sell
-1,735
Closed -$10.4K – 6697
2024
Q2 		$8.02K Buy
+1,735
New +$10.3K ﹤0.01% 5740
2022
Q2 		– Sell
-4,500
Closed -$39.6K – 7858
2022
Q1 		$109K Buy
4,500
+4,000
+800% +$97.1K ﹤0.01% 5404
2021
Q4 		$16K Buy
500
+200
+67% +$7.91K ﹤0.01% 7096
2021
Q3 		$13K Buy
+300
New +$12.8K ﹤0.01% 7375

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Group One Trading's CCCC Position: Q1 2026 in Review

Group One Trading sold out of C4 Therapeutics (CCCC) in Q1 2026, closing a stake of 38,994 shares — an estimated $91.8K sold.

Group One Trading first reported a position in CCCC in Q3 2021 and held it in 8 quarters. The position peaked at $118K in Q4 2024. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Group One Trading reported no remaining C4 Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 38,994 C4 Therapeutics shares in Q1 2026, an estimated $91.8K.
  • Group One Trading first reported a position in C4 Therapeutics in Q3 2021 and held it in 8 quarters.
  • Group One Trading's C4 Therapeutics position peaked at $118K in Q4 2024.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.